Skip to Main Content (Press Enter)

Logo UNINSUBRIA
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNINSUBRIA

|

UNI-FIND

uninsubria.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Extended thromboprophylaxis with betrixaban in acutely ill medical patients

Articolo
Data di Pubblicazione:
2016
Abstract:
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated D-dimer level (cohort 1), patients with an elevated D-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. RESULTS: A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P = 0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P = 0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P = 0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P = 0.55). CONCLUSIONS: Among acutely ill medical patients with an elevated D-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts.
Tipologia CRIS:
Articolo su Rivista
Elenco autori:
Cohen, A. T.; Harrington, R. A.; Goldhaber, S. Z.; Hull, R. D.; Wiens, B. L.; Gold, A.; Hernandez, A. F.; Gibson, C. M.; Bello, F.; Ferrari, A. E.; Jure, H.; Macin, S.; Oliva, M.; Parody, M.; Poy, C.; Baker, R.; Colquhoun, D.; Coughlin, P.; Finfer, S.; Rubinfeld, A.; Huber, K.; Konig, J.; Mathies, R.; Pilger, E.; Schoenerr, H.; Adzerikho, I.; Koryk, V.; Mikhailova, E.; Mitkovskaya, N.; Pimanov, S.; Polonetsy, L.; Soroka, N.; Blockmans, D.; Delforge, M.; Dive, A.; Lienart, F.; Motte, S.; Bizzacchi, J.; Fiss, E.; Freire, A.; Manenti, E.; Ramacciotti, E.; Raymuno, S.; Rocha, A.; Saraiva, J. F.; Dimov, B.; Grigorov, M.; Kalpachki, R.; Kamenova, Z.; Kostadinova, M.; Milanova, M.; Mincheva, V.; Pencheva, G.; Raev, D.; Runev, N.; Stoeva, N.; Stoyanov, M.; Syulemzova, S.; Todorov, G.; Tokmakova, M.; Dhar, A.; Douketis, J.; Kahn, S.; Le Gal, G.; Pearce, M.; Provencher, S.; Verreault, S.; Alarcon, M.; Canon, C.; Lazcano, M.; Cardenas, S.; Butkovic-Soldo, S.; Car, S.; Ciglenecki, N.; Francetic, I.; Jakopovic, M.; Kalinic-Grgorinic, H.; Knezevic, A.; Malojcic, B.; Marusic, S.; Vagic, J.; Skerk, V.; Cermak, O.; Chlumsky, J.; Chochola, J.; Cizek, V.; Dunaj, M.; Dusek, J.; Francek, L.; Havelka, J.; Herold, M.; Holaj, R.; Horny, I.; Hubac, J.; Jajtner, P.; Kolman, P.; Lang, P.; Mayer, O.; Mikulova, J.; Podpera, I.; Reiterer, P.; Spacek, R.; Vejvoda, J.; Vyhnanek, M.; Christensen, H.; Lassen, M.; Storgaard, M.; Tuxen, C.; Urhammer, S.; Lember, M.; Marandi, T.; Uuetoa, T.; Airaksinen, J.; Honkaniemi, J.; Kaaja, R.; Lassila, R.; Saarinen, J.; Tatlisumak, T.; Vikman, S.; Agraou, B.; Aquilanti, S.; Belhassane, A.; Brisot, D.; De Geeter, G.; Debourdeau, P.; Decoulx, E.; El Kouri, D.; Falvo, N.; Grange, C.; Lacroix, P.; Messas, E.; Mismetti, P.; Montaclair, K.; Mottier, D.; Paleiron, N.; Payot, L.; Pernod, G.; Pottier, P.; Proust, A.; Quere, I.; Roy, P. M.; Schmidt, J.; Simoneau, G.; Datikashvili-David, I.; Khabeishvili, G.; Khintibidze, I.; Kobulia, B.; Megreladze, I.; Pagava, Z.; Paposhvili, K.; Shaburishvili, T.; Amann, B.; Berrouschot, J.; Beyer-Westendorf, J.; Blessing, E.; Bott, M.; Dengler, T.; Dziewas, R.; Genth-Zotz, S.; Hamann, F.; Horacek, T.; Klimpe, S.; Kroning, R.; Lapp, H.; Lawall, H.; Licka, M.; Rizos, T.; Schellong, S.; Tiefenbacher, C.; Weimar, C.; Zeymer, U.; Alkonyi, B.; Falukozy, J.; Futo, L.; Katona, A.; Kirschner, R.; Kristof, P.; Lakatos, F.; Laszlo, Z.; Lupkovics, G.; Merkely, B.; Andras, C.; Nemeth, L.; Papp, A.; Soltesz, P.; Sudar, Z.; Szabo, G.; Szegedi, N.; Timar, G.; Valco, J.; Vertes, A.; Efrati, S.; Elias, M.; Gafter, A.; Hayek, T.; Hussein, O.; Lishner, M.; Lugassy, G.; Zeltser, D.; Ageno, W.; Cerveri, I.; D'Angelo, A.; De Pellegrin, A.; Imberti, D.; Landolfi, R.; Lembo, G.; Lodigiani, C.; Moia, M.; Molteni, M.; Mumoli, N.; Novo, S.; Orlandini, F.; Parisi, R.; Pizzini, A.; Pomero, F.; Salvi, A.; Schenone, A.; Visona, A.; Krievins, D.; Martinova, V.; Pontaga, N.; Rozitis, V.; Stukena, I.; Alekniene, B.; Bagdonas, A.; Basijokiene, V.; Butkiene, Z.; Griskeviciene, V.; Naudziunas, A.; Norvaisiene, R.; Norviliene, R.; Petrauskiene, R.; Poskiene, R.; Susinskiene, D.; Valavicius, A.; Leon, R.; Pereyra, R.; Karlo, L.; Horna, M.; Osores, J.; Salas, M.; Yanez, L.; Fryze, W.; Gaciong, Z.; Gniot, J.; Gorecka, D.; Gruenpeter, P.; Grzelakowski, P.; Jastrzebski, D.; Kucharski, L.; Mirek-Bryniarska, E.; Pulkowski, G.; Sobkowicz, B.; Sulik, P.; Tomkowski, W.; Walasek, L.; Waldemar, K.; Wrzesinski, K.; Balogh, Z. E.; Bojinca, M.; Marin, I.; Mot, S.; Musetescu, R.; Podoleanu, C.; Popescu, M.; Stamate, S.; Stanciulescu, G.; Vida-Simiti, L.; Abashev, A.; Andreev, D.; Apartsin, K.; Arkhipov, M.; Averkov, O.; Barbarash, O.; Belskaya, G.; Bogdanov, E.; Boldueva, S.; Chefranova, Z.; Dovgalevskiy, Y.; Ershova, O.; Goloshchekin, B.; Khachatryan, N.; Klein, G.; Kobalava, Z.; Kosmacheva, E.; Kostenko, V.; Malygin, A.; Martynenko, T.; Martynenko, V.; Maslova, N.; Mordovin, V.; Nikolaev, K.; Nilk, R.; Panchenko, E.; Popov, D.; Privalova, E.; Reshe
Link alla scheda completa:
https://irinsubria.uninsubria.it/handle/11383/2098278
Pubblicato in:
THE NEW ENGLAND JOURNAL OF MEDICINE
Journal
  • Accessibilità
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.1.0